• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

IIIM-290

(CAS: 2213468-64-3 )

Suppliers of IIIM-290

Company Name Email Tel Country
MedKoo Biosciences, Inc. [email protected] 919-279-0682 USA

Fax: 919-980-4831Purity: Brand:

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:
Remarks:
 

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of IIIM-290

IIIM-290 is an orally active potent cyclin-dependent kinase inhibitor. IIIM-290 shows strong inhibition of Cdk-9/T1 (IC50 1.9 nM) kinase and Molt-4/MIAPaCa-2 cell growth (GI50<1.0 μM) and is found to be highly selective for cancer cells over normal fibroblast-cells. IIIM-290 inhibits the cell growth of MIAPaCa-2 cells via caspasedependent apoptosis. IIIM-290 achieves 71% oral bioavailability with in-vivo efficacy in pancreatic, colon and leukemia xenografts at 50 mg/kg, po.

Solubility of IIIM-290

Solubility Sources

Storage Condition of IIIM-290

Storage Condition Sources

MSDS Information

MSDS Sources

Quality Control and Spectral Data

QC Reports Sources

Mechanism and Indications

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase

Chemical Information

M.Wt Formula CAS No. Synonyms
462.32 C23H21Cl2NO5 2213468-64-3 IIIM-290; IIIM 290; IIIM290.

Structure Information of IIIM-290

Smiles C1(O)C2C(C=C(/C=C/C3C(Cl)=CC=CC=3Cl)OC=2C([[email protected]@]2([H])CCN(C)C[[email protected]]2O)=C(O)C=1)=O |&1:19,26|
InChI InChI=1S/C23H21Cl2NO5/c1-26-8-7-14(20(30)11-26)21-18(28)10-19(29)22-17(27)9-12(31-23(21)22)5-6-13-15(24)3-2-4-16(13)25/h2-6,9-10,14,20,28-30H,7-8,11H2,1H3/b6-5+/t14-,20+/m0/s1

Related Products

Other Form Products of IIIM-290

Name CAS Formula Suppliers

Recommended Products in Same Target

Name CAS Formula Suppliers
LY2857785 1619903-54-6 C26H36N6O 12
THZ2 1604810-84-5 C31H28ClN7O2 10
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 22
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 5
ML167 1285702-20-6 C19H17N3O3 15
AMG 925 1401033-86-0 C26H29N7O2 15
LDC000067 1073485-20-7 C18H18N4O3S 11
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 8
LEE011 (succinate) 1374639-75-4 C27H36N8O5 9
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 8
LEE011 1211441-98-3 C23H30N8O 21
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 6
Wogonin 632-85-9 C16H12O5 28
1-NM-PP1 221244-14-0 C20H21N5 17
WHI-P180 211555-08-7 C16H15N3O3 13
THZ1 1604810-83-4 C31H28ClN7O2 18
Senexin A 1366002-50-7 C17H14N4 8
CDK4-IN-1 1256963-02-6 C22H29ClN8 9
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 16
Purvalanol B 212844-54-7 C20H25ClN6O3 22

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:Soluble in DMSO
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:

Reference

[1].Bharate SB, et al. Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-dependent Kinase Inhibitor. J Med Chem. 2018 Jan 25.
Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via IV route. With the objective to address oral bioavailability issue of this scaffold, four series of rohitukine derivatives were prepared and screened for Cdk inhibition and cellular antiproliferative activity. The 2,6-dichloro-styryl derivative IIIM-290 (11d) showed strong inhibition of Cdk-9/T1 (IC50 1.9 nM) kinase and Molt-4/MIAPaCa-2 cell growth (GI50 < 1.0 µM) and was found to be highly selective for cancer cells over normal fibroblast-cells. It inhibited the cell growth of MIAPaCa-2 cells via caspase-dependent apoptosis. It achieved 71% oral bioavailability with in-vivo efficacy in pancreatic, colon and leukemia xenografts at 50 mg/kg, po. It did not have CYP/ efflux-pump liability, was not mutagenic/genotoxic or cardiotoxic and was metabolically-stable. The preclinical data presented herein indicates the potential of 11d for advancement in clinical studies.

Tags: buy IIIM-290 | IIIM-290 IC50 | IIIM-290 price | IIIM-290 cost | IIIM-290 solubility | IIIM-290 purchase | IIIM-290 manufacturer | IIIM-290 research buy | IIIM-290 order | IIIM-290 MSDS | IIIM-290 chemical structure | IIIM-290 Storage condition | IIIM-290 molecular weight | IIIM-290 mw | IIIM-290 datasheet | IIIM-290 supplier | IIIM-290 cell line | IIIM-290 NMR | IIIM-290 MS | IIIM-290 IR | IIIM-290 solubility | IIIM-290 Safe information | IIIM-290 Qc and Spectral Information | IIIM-290 Clinical Information | IIIM-290 Clinical Trial | IIIM-290 Route of Synthesis | IIIM-290 storage condition | IIIM-290 diseases and conditions | IIIM-290 flash point | IIIM-290 boiling point | IIIM-290 melting point | IIIM-290 storage condition | IIIM-290 brand